Tracing Resource Usage over Heterogeneous Grid Platforms: A Prototype RUS Interface for DGAS

Tracing resource usage by Grid users is of utmost importance especially in the context of large-scale scientific collaborations such as within the High Energy Physics (HEP) community to guarantee fairness of resource sharing, but many difficulties can arise when tracing the resource usage of distributed applications over heterogeneous Grid platforms. These difficulties are often related to a lack of interoperability of the accounting components across middlewares. This paper brie y describes the architecture and workflow of the Distributed Grid Accounting System (DGAS) [1] and evaluates the possibility to extend it with a Resource Usage Service (RUS) [2, 3] interface according to the Open Grid Forum (OGF) sped cation that allows to store and retrieve OGF Usage Records (URs) [4, 5] via Web Services. In this context the OGF RUS and UR sped cations are critically analyzed. Furthermore, a prototype of a RUS interface for DGAS (DGAS-RUS) is presented and the most recent test results towards a full interoperability between heterogeneous Grid platforms are outlined

Image Compression for the Silicon Drift Detectors in the ALICE Experiment

The output of each Silicon Drift Detector in the Inner Tracking System, being prepared for the future ALICE Experiment on the LHC, is a type of image composed of 256 successive digitilizations from each of 256 parallel charge measuring channels. We describe an algorithm for the zero suppression and data compression for the Silicon Drift Detectors in the ALICE Experiment, which seeks to maintain maximum precision within the limits of data transmission bandwidth, to retain two-dimensional cluster reconstructability and to statistically monitor the background.(Abstract only available, full text will follow

The Silicon Drift Detector readout scheme for the Inner Tracking System of the ALICE Experiment

Presentation at Quark Matter '99, Torino, Italy, 10-15 May 1999The Silicon Drift Detectors (SDDs) provide, through the measurement of the drift time of the charge deposited by the particle which crosses the detector, information on the impact point and on the energy deposition. The foreseen readout scheme is based on a single chip implementation of an integrated circuit that includes low-noise amplification, fast analog strorage and analog to digital conversion, thus avoiding the problems related to the analog signal transmission. A multi-event buffer that reduces the transmission bandwidth and a data compression/zero suppression unit complete the architecture.Abstract:In this paper, the system components design is described, together with the results of the first prototypes

Test Results of the ALICE SDD Electronic Readout Prototypes

The first prototypes of the front-end electronics of the ALICE silicon driftdetectors have been designed and tested. The integrated circuits have been designed using state of the art technologies and, for the analog parts, with radiation-tolerantdesign techniques. In this paper, the test results of the building blocks of the PASCAL chip and the first prototype of the AMBRA chip are presented. The prototypes fully respect the ALICE requirements; owingto the use of deep-submicron technologies together with radiation-tolerant layout techniques, the prototypes have shown a toleranceto a radiation dose much higher than the one foreseen for the ALICE environment.(Abstract only available, full text to follow)

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to confirm the phase II results and to detect an overall survival (OS) benefit. PATIENTS AND METHODS: Men with chemotherapy-naïve mCRPC and evidence of bone metastases were assigned (2:1) to receive tasquinimod once per day or placebo until progression or toxicity. The primary end point was radiographic PFS (rPFS; time from random assignment to radiologic progression or death) per Prostate Cancer Working Group 2 criteria and RECIST 1.1. The study had 99.9% power to detect an rPFS hazard ratio (HR) of 0.6 with a two-sided alpha error of .05 and 80% power to detect a target HR of 0.8 for OS, the key secondary end point. RESULTS: In all, 1,245 patients were randomly assigned to either tasquinimod (n = 832) or placebo (n = 413) between March 2011 and December 2012 at 241 sites in 37 countries. Baseline characteristics were balanced between groups: median age, 71 years; Karnofsky performance status ≥ 90%, 77.3%; and visceral metastases, 21.1%. Estimated median rPFS by central review was 7.0 months (95% CI, 5.8 to 8.2 months) with tasquinimod and 4.4 months (95% CI, 3.5 to 5.5 months) with placebo (HR, 0.64; 95% CI, 0.54 to 0.75; P < .001). Median OS was 21.3 months (95% CI, 19.5 to 23.0 months) with tasquinimod and 24.0 months (95% CI, 21.4 to 26.9 months) with placebo (HR, 1.10; 95% CI, 0.94 to 1.28; P = .25). Grade ≥ 3 adverse events were more frequent with tasquinimod (42.8% v 33.6%), the most common being anemia, fatigue, and cancer pain. CONCLUSION: In chemotherapy-naïve men with mCRPC, tasquinimod significantly improved rPFS compared with placebo. However, no OS benefit was observed

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.

Background Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between these two drugs when used sequentially, but robust, prospective studies have not yet been reported.Objective To fulfil a regulatory postregistration commitment by evaluating the efficacy and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed following abiraterone acetate plus prednisone treatment.Design, setting, and participants Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment. All patients maintained castration therapy during the trial. Prior chemotherapy was allowed but not required.Intervention Patients received enzalutamide 160mg/d orally.Outcome measurements and statistical analysis The primary endpoint was radiographic progression-free survival. Secondary endpoints were overall survival, prostate-specific antigen (PSA) response, and time-to-PSA progression. Safety data were also assessed. Kaplan-Meier methods were used to descriptively analyse time-to-event endpoints.Results and limitations Overall, 214 patients received enzalutamide treatment, 145 of whom were chemotherapy-naïve. Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached. Unconfirmed PSA response rate was 27% (48 of 181). Median time-to-PSA progression was 5.7 mo (95% confidence interval: 5.6-5.8). The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%). No seizures were reported.Conclusions Enzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment.Patient summary Patients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment

Pathogenic Bacillus anthracis in the progressive gene losses and gains in adaptive evolution

Background: Sequence mutations represent a driving force of adaptive evolution in bacterial pathogens. It is especially evident in reductive genome evolution where bacteria underwent lifestyles shifting from a free-living to a strictly intracellular or host-depending life. It resulted in loss of function mutations and/or the acquisition of virulence gene clusters. Bacillus anthracis shares a common soil bacterial ancestor with its closely related bacillus species but is the only obligate, causative agent of inhalation anthrax within the genus Bacillus. The anthrax-causing Bacillus anthracis experienced the similar lifestyle changes. We thus hypothesized that the bacterial pathogen would follow a compatible evolution path. Results: In this study, a cluster-based evolution scheme was devised to analyze genes that are gained by or lost from B. anthracis. The study detected gene losses/gains at two separate evolutionary stages. The stage I is when B. anthracis and its sister species within the Bacillus cereus group diverged from other species in genus Bacillus. The stage II is when B. anthracis differentiated from its two closest relatives: B. cereus and B. thuringiensis. Many genes gained at these stages are homologues of known pathogenic factors such those for internalin, B. anthracis-specific toxins and large groups of surface proteins and lipoproteins. Conclusion: The analysis presented here allowed us to portray a progressive evolutionary process during the lifestyle shift of B. anthracis, thus providing new insights into how B. anthracis had evolved and bore a promise of finding drug and vaccine targets for this strategically important pathogen